ArticleThe Analyst2009
A microfluidic technique for monitoring bloodstream analytes indicative of C-peptide resistance in type 2 diabetes.
Article in The Analyst, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 10 citations in OpenAlex.
- Simplifying the complex: accessible microfluidic solutions for contemporary processes withinLab on a chip · 2022Review
- Review: Microfluidic applications in metabolomics and metabolic profiling.Analytica chimica acta · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
A simple poly(dimethylsiloxane) (PDMS) microchip was employed to establish a relationship between red blood cell (RBC) antioxidant status and the ability of RBCs to interact with metal-activated C-peptide, a bio-active peptide reported to reduce some complications often associated with diabetes. It is known that the reduced form of glutathione (GSH) levels in the RBCs obtained from people with type 2 diabetes are lower in comparison to those RBCs obtained from healthy controls and accordingly, this correlation has the potential to implicate type 2 diabetes in high-risk individuals. A parallel channel microfluidic device for the quantification of GSH in age-based fractions, along with control and diabetic RBCs is described. Important to the fluorescence-based measurement is the simultaneous determination of the antioxidant without prior separation in either a six- or twelve-channel microchip. Here, we separated the RBCs using a density-based Percoll solution and quantitatively determined the concentration of GSH in younger, less dense RBCs to be increased more than 2-fold (336.7 +/- 29.6 amol/RBC) than older, more dense RBCs (137.0 +/- 25.3 amol/RBC). The ability of C-peptide to interact with the RBC membrane of the separated fractions was determined by immunoassay and it was found that the recovery of the C-peptide added to the younger RBCs increased by more than 40.6 +/- 12.7% above basal levels while with the older cells C-peptide increased by only 9.18 +/- 4.60%. These results suggest that GSH concentrations in the RBC may be useful in screening for resistance to C-peptide in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.